Not actual patients.
How it works
An innovative approach to hemophilia treatment
HYMPAVZI is designed to help restore balance in the clotting process—independent of factor VIII or IX levels—by targeting TFPI.
Why is balance important?
In people without hemophilia, anticlotting factors and clotting factors work in balance like a scale so the body can clot when needed—without causing too much clotting or too much bleeding.
In people with hemophilia, there is a lack of clotting factors, causing the scale to tip toward bleeding.
How does HYMPAVZI help restore balance?
HYMPAVZI uses an innovative approach that may help restore the balance by targeting TFPI to decrease anticlotting activity.
Blocking the activity of TFPI increases the tendency to develop thrombin, which may improve clotting function.
This could potentially help the body prevent or reduce the frequency of bleeding episodes.
Because HYMPAVZI works in an innovative way to block TFPI instead of replacing factor, it works independent of factor VIII or factor IX levels.
APC=activated protein C; AT=antithrombin; TFPI=tissue factor pathway inhibitor. These do not represent all of the anticlotting and clotting factors in the body.
See the clinical trial design